Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This product helps improve lung function and oxygenation, often administered via endotracheal tube.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs lack sufficient surfactant, a substance that keeps the air sacs open. By replenishing surfactant, Curosurf aids in improving lung compliance and reducing the work of breathing. It is typically administered via endotracheal tube to deliver the medication directly into the lungs.

Curosurf works by replacing the natural surfactant in the lungs, which helps to reduce surface tension and prevent the collapse of alveoli. This action can lead to improved oxygenation and reduced respiratory effort in premature infants. The effects are generally observed shortly after administration.

Curosurf should be administered by trained healthcare professionals in a controlled medical setting. It is essential to follow proper handling and storage guidelines to maintain the efficacy of the product. Always consult a healthcare provider for specific precautions and contraindications.

Curosurf is generally used in a clinical setting where interactions with other medications are carefully monitored. However, it is important to inform healthcare providers about any other medications or treatments the infant is receiving to avoid potential complications.